Company intelligence / Profile preview

Flindr Therapeutics

Ownership: Private
Development stage: Other

Overview

Developing first-in-class small molecule inhibitors for precision treatment of cancer. Their lead program targets RNF31, which when inhibited destabilizes two proteins that switch cancer cells from survival to cell death.

Therapeutic areas: Oncology
Modalities: Small molecule inhibitors
Industry: Biotech

Drug pipeline

1 asset

RNF31 inhibitor

Unknown

Partnerships

Netherlands Cancer Institute (NCI)Oncode InstituteVlaams Institute voor Biotechnologie (VIB)

Beyond the preview

Go deeper on Flindr Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flindr Therapeutics.